For licensed healthcare professionals. The protocol figures below are drawn from published labeling and peer-reviewed literature for educational reference. They are not a prescription, not a recommendation, and not a substitute for the dispensing pharmacy's labeling or your own clinical judgment.

GH Secretagogue

CJC-1295 (no DAC)

aka Modified GRF 1-29

WADA prohibited

GHRH analog often stacked with ipamorelin to amplify endogenous GH pulses. WADA-prohibited.

At a glance

Common vial size: 5 mg
Reference dose: 100 mcg
Frequency: 1–3× daily

Reference titration protocol

Flat 100 mcg, 1–3× daily; often stacked with ipamorelin.

Reference titration ladder for CJC-1295 (no DAC)
Step	Dose	Duration	Administrations / week
1	100 mcg	4 weeks	21×

Reconstitution example

A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. Confirm the diluent and volume against the labeling that ships with the vial.

Open this configuration in the calculator

Available formulations

Presentations carried across the VitaRelay pharmacy network, including 503A compounded, 503B outsourcing facility, and research & development sourcing. Pricing and state-level availability are shown to verified accounts only.

0 · Pen503B
Injectable503A
Lyophilized PowderRUO

References

WADA Prohibited List

Often used with

Compounds commonly discussed alongside CJC-1295 (no DAC) in published protocols and prescriber requests. Listed for reference only — not a clinical recommendation, and not a suggestion to co-administer.

Pricing and ordering are for verified accounts

VitaRelay serves licensed practices, prescribers, and pharmacies. Catalog pricing, availability by state, and ordering are available after your account is verified.

Also in GH Secretagogue

Sermorelin

GHRH 1-29 analog that stimulates pulsatile endogenous GH release. Historically FDA-approved (Geref, withdrawn 2008); now compounded.

Tesamorelin

Stabilized GHRH analog FDA-approved for HIV-associated lipodystrophy. Often compounded with ipamorelin in anti-aging protocols.

Ipamorelin

Selective ghrelin/GHS-R agonist that triggers pulsatile GH release with minimal cortisol or prolactin impact. WADA-prohibited.

GHRP-2

Synthetic hexapeptide ghrelin-receptor agonist. Stronger GH release than GHRP-6 with less appetite stimulation.

GHRP-6

Ghrelin-receptor agonist with marked appetite-stimulant effect. Often stacked with a GHRH (sermorelin or CJC-1295).

Hexarelin

Potent GH secretagogue with longer-lasting effect than GHRP-6; receptor desensitization can occur with chronic high doses.

Educational information for licensed healthcare professionals

The material on this page is general educational information intended for licensed healthcare professionals and their clinical staff. It is not medical advice, is not a substitute for professional judgment, and does not establish a provider-patient relationship. Nothing here should be read as a recommendation for, or endorsement of, any specific therapy, product, or course of treatment. Compounded preparations must be handled in accordance with applicable federal and state law, the dispensing pharmacy's labeling, and your own institutional policies. All clinical decisions — including product selection, preparation, dosing, and administration — remain the sole responsibility of the treating licensed practitioner.

VitaRelay is a technology and logistics network. We are not a pharmacy, prescriber, or distributor. See our Terms of Service and service availability for details.